CANSINOBIO (06185) climbed nearly 6% again; as of writing, the stock was up 4.02%, trading at HK$38.8 with a turnover of HK$30.0975 million. The company announced that its self-developed 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid, referred to as "PCV24") has officially received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, granting approval to commence clinical trials. As of the announcement date, there are no 24-valent pneumococcal conjugate vaccine products available on the market globally. According to the announcement, PCV24 has completed the development and validation of the purification processes for 24 serotype polysaccharides, the manufacturing process for polysaccharide-protein conjugate bulk, and the final formulation; it covers the major currently prevalent pneumococcal serotypes. The vaccine utilizes covalent conjugation of polysaccharide antigens to protein carriers and a dual-carrier technology, and is intended for active immunization of individuals aged 2 months (minimum 6 weeks) and above to prevent infectious diseases caused by the 24 pneumococcal serotypes. PCV24 represents the company's advancement in developing higher-valent pneumococcal conjugate vaccines, building upon its existing technological expertise. The company stated that this approval further enriches and enhances its research and development pipeline in the field of pneumococcal conjugate vaccines.